Fog City Capital
VC Fund
San Francisco, United States
Fog City Capital is a private equity firm focused exclusively on investments in outsourced business services and technologies within those sectors.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Fog City Capital invests in
BiotechnologyHealth CareMedical DeviceMedicalAdvertising
Stages Fog City Capital invests in
Series ASeries BSeries CSeedSeries D
Countries Fog City Capital invests in
United StatesUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nancy Olson
|
|||
Investment Focus
Industry
- Biotechnology 5 (33%)
- Health Care 4 (27%)
- Medical Device 3 (20%)
- Medical 2 (13%)
- Advertising 2 (13%)
Stage
- Series A 5 (33%)
- Series B 5 (33%)
- Series C 2 (13%)
- Seed 1 (7%)
- Series D 1 (7%)
Country
- United States 8 (53%)
- United Kingdom 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Nancy Olson
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
FCTRY LAb
|
Fctry lab combine traditional manufacturing methods with modern technology, allowing us to redefine techniques and invent new construction methods | $8M / Series A / Mar 11, 2025 | |
|
FCTRY LAb
|
Fctry lab combine traditional manufacturing methods with modern technology, allowing us to redefine techniques and invent new construction methods | $6M / Seed / Dec 14, 2022 | |
Ad-Lib.io
|
Ad-Lib is a digital creative tech and service business. The only UK based Double Click Creative Marketing Partner, We are a tech business that can help transform your online creative ability! We work with both Doubleclick and Facebook to improve the deployment of digital creative. We dont buy media, we just deliver excellent, optimised creative.-Dynamic Video offering - Integration with Facebook and Doubleclcick - A/B testing - Optimisation algorythem - Full preview solution - No double ad serving - Time savings of up to 46% - Performance uplift of up to 80% - Full service offering provided | $6M / Series A / Feb 16, 2021 | |
|
Ad-Lib.io
|
Ad-Lib is a digital creative tech and service business. The only UK based Double Click Creative Marketing Partner, We are a tech business that can help transform your online creative ability! We work with both Doubleclick and Facebook to improve the deployment of digital creative. We dont buy media, we just deliver excellent, optimised creative.-Dynamic Video offering - Integration with Facebook and Doubleclcick - A/B testing - Optimisation algorythem - Full preview solution - No double ad serving - Time savings of up to 46% - Performance uplift of up to 80% - Full service offering provided | Series A / Nov 19, 2019 | |
Visual IQ
|
Visual IQ produces the world’s most powerful cross channel marketing attribution software products. As a pioneer in the space, the company has been offering products since 2006. Its SaaS-based IQ Intelligence Suite reveals cross channel performance insights hidden deep within companies’ marketing data, providing actionable recommendations andoptimized media plans to improve marketing effectiveness. These recommendations enable marketers and agencies to adjust their advertising strategies and tactics to significantly increase marketing ROI across their entire marketing mix – both online and offline. The functionality behind these products combines a powerful, user-friendly interface with multi-dimensional fractional attribution science and predictive analytics that clearly and accurately show marketers where opportunities exist for improvement.Visual IQ was named a leader in cross channel attribution in 2014 by a leading market research firm, won The Drum's 2015 Digital Trading Award for Best Attribution Solution, won the 2014 ASPY Award for Best Data or Analytics Solution, and was a finalist in the Digital Analytics Association Excellence Awards in 2013, 2014 and 2015. The company is a member of the Advertising Technology, Data, Public Policy and CFO Councils of the IAB, as well as on the Standards Committee of the Digital Analytics Association. | $12M / Series B / Jun 25, 2012 | |
Cianna Medical
|
Cianna Medical, Inc. is a women's health company dedicated to the innovative treatment of early-stage breast cancer. When diagnosed early, most women have the option to save their breast by choosing breast conservation therapy (BCT). Their mission is to make BCT available to more women, by developing new approaches to delivering follow-upradiation therapy. | $12M / Series B / Apr 28, 2011 | |
|
Visual IQ
|
Visual IQ produces the world’s most powerful cross channel marketing attribution software products. As a pioneer in the space, the company has been offering products since 2006. Its SaaS-based IQ Intelligence Suite reveals cross channel performance insights hidden deep within companies’ marketing data, providing actionable recommendations andoptimized media plans to improve marketing effectiveness. These recommendations enable marketers and agencies to adjust their advertising strategies and tactics to significantly increase marketing ROI across their entire marketing mix – both online and offline. The functionality behind these products combines a powerful, user-friendly interface with multi-dimensional fractional attribution science and predictive analytics that clearly and accurately show marketers where opportunities exist for improvement.Visual IQ was named a leader in cross channel attribution in 2014 by a leading market research firm, won The Drum's 2015 Digital Trading Award for Best Attribution Solution, won the 2014 ASPY Award for Best Data or Analytics Solution, and was a finalist in the Digital Analytics Association Excellence Awards in 2013, 2014 and 2015. The company is a member of the Advertising Technology, Data, Public Policy and CFO Councils of the IAB, as well as on the Standards Committee of the Digital Analytics Association. | $3M / Series A / Aug 20, 2010 | |
|
Cianna Medical
|
Cianna Medical, Inc. is a women's health company dedicated to the innovative treatment of early-stage breast cancer. When diagnosed early, most women have the option to save their breast by choosing breast conservation therapy (BCT). Their mission is to make BCT available to more women, by developing new approaches to delivering follow-upradiation therapy. | $9M / Series A / Feb 26, 2008 | |
Proprius Pharmaceuticals
|
Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005. | $11M / Series A / Jan 08, 2007 | |
Somaxon Pharmaceuticals
|
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketingproprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States. | $23M / Series B / Jun 15, 2004 | |
| See all 15 investments → | |||
Co-Investors
Windamere Venture Partners
6 deals together
St. Paul Venture Capital
5 deals together
Domain Associates
3 deals together
Advent Venture Partners
2 deals together
CDIB BioScience Ventures
2 deals together
Elysian Park Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Enterprise Investors
77,348 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Enterprise VC Funds
49,693 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
FAQ
What does Fog City Capital invest in?
Fog City Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fog City Capital?
Public channels for Fog City Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fog City Capital?
The team at Fog City Capital includes Nancy Olson (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
